Tuesday, May 21 • 1:00am – 12:00pm

With Special Guests – The Open Payments Team

Growing state and global transparency initiatives continue to cause increasing concern within our industry. Federal reporting under Open Payments continues to be more and more challenging, and managing compliance across multiple reporting entities may be compromised as companies try to keep up.

Attend this open conversation Town Hall and you’ll have the opportunity to address questions to the CMS Team either in person or by submitting questions prior to the conference. This is a great way to get clarity on new or specific federal requirements and to share any challenges manufacturers may be facing when compiling required Federal reports.

Are you wondering what CMS is looking for in the reporting and what they are doing with the data that is being collected? Would you like them to understand your pain points when submitting data? Would you like to learn best practices for being compliant with Open Payments reporting?

Remember, our compliance goals are the same. This is a special occasion to interact directly with CMS in an open and comfortable setting and have your transparency-related questions discussed and answered directly by the agency.

Wednesday, May 22 • 9:30am – 10:30am

An overview of the current opioid crisis, DEA’s latest initiatives and a variety of diversion-related topics

Presented by:
Scott A. Brinks
Section Chief, Diversion Regulatory Drafting & Policy Support Section (DPW), Drug Enforcement Administration

Niketa G. Prince
Staff Coordinator (DI), HQ Liaison Section, Diversion Control Division, Drug Enforcement Administration

As many of you may know, the mission of DEA’s Diversion Control Division is to prevent, detect,
and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate
sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs. Under federal law, all businesses that import, export, manufacture, or distribute controlled substances must register with the DEA and must comply with regulatory requirements relating to drug security and record-keeping for controlled substances.

These regulations can sometimes be as confusing to well-seasoned professionals as they are to those who are new to working with controlled substances. This session will provide conference attendees with an opportunity to hear what’s new and get answers to questions they might find challenging.

Questions submitted in advance of the General Session will be answered during the time allotted for discussion. Details on how to send in anonymous questions or submit them at the conference will be emailed to registered attendees in May.